世界のオマリズマブ・バイオシミラー市場予測（～2028年）：150 mg/mL、 75 mg/0.5 mL

• 英文タイトル：Global Omalizumab Biosimilars Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

• レポートコード：GIR-22E8909 • 出版社/出版日：GlobalInfoResearch / 2022年5月 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

オマリズマブ・バイオシミラー市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界のオマリズマブ・バイオシミラーの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 オマリズマブ・バイオシミラー市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・150 mg/mL、 75 mg/0.5 mL 用途別セグメントは次のように区分されます。 ・持続性喘息、鼻ポリープ、慢性特発性蕁麻疹 世界のオマリズマブ・バイオシミラー市場の主要な市場プレーヤーは以下のとおりです。 ・Roche、Novartis、Glenmark Pharmaceuticals、Selexis、Generium、CuraTeQ、Celltrion Healthcare、Alvotech、BiosanaPharma、Mabpharm、CSPC Pharmaceutical Group、Biomabs、HisunPharm、Grand Pharm 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、オマリズマブ・バイオシミラー製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要なオマリズマブ・バイオシミラーメーカーの企業概要、2019年～2022年までのオマリズマブ・バイオシミラーの価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要なオマリズマブ・バイオシミラーメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別オマリズマブ・バイオシミラーの販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までのオマリズマブ・バイオシミラーの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのオマリズマブ・バイオシミラー市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、およびオマリズマブ・バイオシミラーの産業チェーンを掲載しています。 ・第13、14、15章では、オマリズマブ・バイオシミラーの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Roche、Novartis、Glenmark Pharmaceuticals、Selexis、Generium、CuraTeQ、Celltrion Healthcare、Alvotech、BiosanaPharma、Mabpharm、CSPC Pharmaceutical Group、Biomabs、HisunPharm、Grand Pharm ・メーカー別市場シェア ・地域別市場分析2017年-2028年 ・種類別分析2017年-2028年：150 mg/mL、 75 mg/0.5 mL ・用途別分析2017年-2028年：持続性喘息、鼻ポリープ、慢性特発性蕁麻疹 ・オマリズマブ・バイオシミラーの北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ ・オマリズマブ・バイオシミラーのヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア ・オマリズマブ・バイオシミラーのアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア ・オマリズマブ・バイオシミラーの南米市場規模2017年-2028年：ブラジル、アルゼンチン ・オマリズマブ・バイオシミラーの中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Omalizumab Biosimilars market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Omalizumab Biosimilars market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Persistent Asthma accounting for % of the Omalizumab Biosimilars global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While 150 mg/mL segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Omalizumab Biosimilars include Roche, Novartis, Glenmark Pharmaceuticals, Selexis, and Generium, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Omalizumab Biosimilars market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
150 mg/mL
75 mg/0.5 mL
Market segment by Application can be divided into
Persistent Asthma
Nasal Polyps
Chronic Idiopathic Urticaria
The key market players for global Omalizumab Biosimilars market are listed below:
Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
CuraTeQ
Celltrion Healthcare
Alvotech
BiosanaPharma
Mabpharm
CSPC Pharmaceutical Group
Biomabs
HisunPharm
Grand Pharm
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Omalizumab Biosimilars product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Omalizumab Biosimilars, with price, sales, revenue and global market share of Omalizumab Biosimilars from 2019 to 2022.
Chapter 3, the Omalizumab Biosimilars competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Omalizumab Biosimilars breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Omalizumab Biosimilars market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Omalizumab Biosimilars.
Chapter 13, 14, and 15, to describe Omalizumab Biosimilars sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Omalizumab Biosimilars Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Omalizumab Biosimilars Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 150 mg/mL
1.2.3 75 mg/0.5 mL
1.3 Market Analysis by Application
1.3.1 Overview: Global Omalizumab Biosimilars Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Persistent Asthma
1.3.3 Nasal Polyps
1.3.4 Chronic Idiopathic Urticaria
1.4 Global Omalizumab Biosimilars Market Size & Forecast
1.4.1 Global Omalizumab Biosimilars Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Omalizumab Biosimilars Sales in Volume (2017-2028)
1.4.3 Global Omalizumab Biosimilars Price (2017-2028)
1.5 Global Omalizumab Biosimilars Production Capacity Analysis
1.5.1 Global Omalizumab Biosimilars Total Production Capacity (2017-2028)
1.5.2 Global Omalizumab Biosimilars Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Omalizumab Biosimilars Market Drivers
1.6.2 Omalizumab Biosimilars Market Restraints
1.6.3 Omalizumab Biosimilars Trends Analysis
2 Manufacturers Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Omalizumab Biosimilars Product and Services
2.1.4 Roche Omalizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Omalizumab Biosimilars Product and Services
2.2.4 Novartis Omalizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Glenmark Pharmaceuticals
2.3.1 Glenmark Pharmaceuticals Details
2.3.2 Glenmark Pharmaceuticals Major Business
2.3.3 Glenmark Pharmaceuticals Omalizumab Biosimilars Product and Services
2.3.4 Glenmark Pharmaceuticals Omalizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Selexis
2.4.1 Selexis Details
2.4.2 Selexis Major Business
2.4.3 Selexis Omalizumab Biosimilars Product and Services
2.4.4 Selexis Omalizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Generium
2.5.1 Generium Details
2.5.2 Generium Major Business
2.5.3 Generium Omalizumab Biosimilars Product and Services
2.5.4 Generium Omalizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 CuraTeQ
2.6.1 CuraTeQ Details
2.6.2 CuraTeQ Major Business
2.6.3 CuraTeQ Omalizumab Biosimilars Product and Services
2.6.4 CuraTeQ Omalizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Celltrion Healthcare
2.7.1 Celltrion Healthcare Details
2.7.2 Celltrion Healthcare Major Business
2.7.3 Celltrion Healthcare Omalizumab Biosimilars Product and Services
2.7.4 Celltrion Healthcare Omalizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Alvotech
2.8.1 Alvotech Details
2.8.2 Alvotech Major Business
2.8.3 Alvotech Omalizumab Biosimilars Product and Services
2.8.4 Alvotech Omalizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 BiosanaPharma
2.9.1 BiosanaPharma Details
2.9.2 BiosanaPharma Major Business
2.9.3 BiosanaPharma Omalizumab Biosimilars Product and Services
2.9.4 BiosanaPharma Omalizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Mabpharm
2.10.1 Mabpharm Details
2.10.2 Mabpharm Major Business
2.10.3 Mabpharm Omalizumab Biosimilars Product and Services
2.10.4 Mabpharm Omalizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 CSPC Pharmaceutical Group
2.11.1 CSPC Pharmaceutical Group Details
2.11.2 CSPC Pharmaceutical Group Major Business
2.11.3 CSPC Pharmaceutical Group Omalizumab Biosimilars Product and Services
2.11.4 CSPC Pharmaceutical Group Omalizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Biomabs
2.12.1 Biomabs Details
2.12.2 Biomabs Major Business
2.12.3 Biomabs Omalizumab Biosimilars Product and Services
2.12.4 Biomabs Omalizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 HisunPharm
2.13.1 HisunPharm Details
2.13.2 HisunPharm Major Business
2.13.3 HisunPharm Omalizumab Biosimilars Product and Services
2.13.4 HisunPharm Omalizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 Grand Pharm
2.14.1 Grand Pharm Details
2.14.2 Grand Pharm Major Business
2.14.3 Grand Pharm Omalizumab Biosimilars Product and Services
2.14.4 Grand Pharm Omalizumab Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Omalizumab Biosimilars Breakdown Data by Manufacturer
3.1 Global Omalizumab Biosimilars Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Omalizumab Biosimilars Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Omalizumab Biosimilars
3.4 Market Concentration Rate
3.4.1 Top 3 Omalizumab Biosimilars Manufacturer Market Share in 2021
3.4.2 Top 6 Omalizumab Biosimilars Manufacturer Market Share in 2021
3.5 Global Omalizumab Biosimilars Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Omalizumab Biosimilars Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Omalizumab Biosimilars Market Size by Region
4.1.1 Global Omalizumab Biosimilars Sales in Volume by Region (2017-2028)
4.1.2 Global Omalizumab Biosimilars Revenue by Region (2017-2028)
4.2 North America Omalizumab Biosimilars Revenue (2017-2028)
4.3 Europe Omalizumab Biosimilars Revenue (2017-2028)
4.4 Asia-Pacific Omalizumab Biosimilars Revenue (2017-2028)
4.5 South America Omalizumab Biosimilars Revenue (2017-2028)
4.6 Middle East and Africa Omalizumab Biosimilars Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Omalizumab Biosimilars Sales in Volume by Type (2017-2028)
5.2 Global Omalizumab Biosimilars Revenue by Type (2017-2028)
5.3 Global Omalizumab Biosimilars Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Omalizumab Biosimilars Sales in Volume by Application (2017-2028)
6.2 Global Omalizumab Biosimilars Revenue by Application (2017-2028)
6.3 Global Omalizumab Biosimilars Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Omalizumab Biosimilars Sales by Type (2017-2028)
7.2 North America Omalizumab Biosimilars Sales by Application (2017-2028)
7.3 North America Omalizumab Biosimilars Market Size by Country
7.3.1 North America Omalizumab Biosimilars Sales in Volume by Country (2017-2028)
7.3.2 North America Omalizumab Biosimilars Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Omalizumab Biosimilars Sales by Type (2017-2028)
8.2 Europe Omalizumab Biosimilars Sales by Application (2017-2028)
8.3 Europe Omalizumab Biosimilars Market Size by Country
8.3.1 Europe Omalizumab Biosimilars Sales in Volume by Country (2017-2028)
8.3.2 Europe Omalizumab Biosimilars Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Omalizumab Biosimilars Sales by Type (2017-2028)
9.2 Asia-Pacific Omalizumab Biosimilars Sales by Application (2017-2028)
9.3 Asia-Pacific Omalizumab Biosimilars Market Size by Region
9.3.1 Asia-Pacific Omalizumab Biosimilars Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Omalizumab Biosimilars Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Omalizumab Biosimilars Sales by Type (2017-2028)
10.2 South America Omalizumab Biosimilars Sales by Application (2017-2028)
10.3 South America Omalizumab Biosimilars Market Size by Country
10.3.1 South America Omalizumab Biosimilars Sales in Volume by Country (2017-2028)
10.3.2 South America Omalizumab Biosimilars Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Omalizumab Biosimilars Sales by Type (2017-2028)
11.2 Middle East & Africa Omalizumab Biosimilars Sales by Application (2017-2028)
11.3 Middle East & Africa Omalizumab Biosimilars Market Size by Country
11.3.1 Middle East & Africa Omalizumab Biosimilars Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Omalizumab Biosimilars Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Omalizumab Biosimilars and Key Manufacturers
12.2 Manufacturing Costs Percentage of Omalizumab Biosimilars
12.3 Omalizumab Biosimilars Production Process
12.4 Omalizumab Biosimilars Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Omalizumab Biosimilars Typical Distributors
13.3 Omalizumab Biosimilars Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

---